Targets › DNMT1
17 programs from 15 companies in 276 trials: 149 Phase 2, 111 Phase 1, 11 Phase 3, 5 Phase 4; Oncology, Hematology, Neurology; next expected readout Dec 2026.
DNA methyltransferase that methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. (UniProt, P26358)
Open in Phaseline: the race on DNMT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AbbVie | Azacitidine DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 4 | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS) | Jul 2027 |
| National Cancer Institute (NCI) | Guadecitabine DNA methyltransferase (DNMT) inhibitor | DNMT1, DNMT3A, DNMT3B | Phase 2 | Locally Advanced Unresectable Primary Central Chondrosarcoma | Jan 2027 |
| Taiho Oncology | Azacitidine (ASTX030) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 2 | Myelodysplastic Syndromes | Nov 2027 |
| Bristol-Myers Squibb | Azacitidine (BMS-986345) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 2 | Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Angioimmunoblastic T-cell Lymphoma (AITL) … | Jul 2028 |
| Virginia Commonwealth University | Decitabine-cedazuridine DNA methyltransferase inhibitor (hypomethylating agent) | DNMT1 | Phase 2 | Relapsed / Refractory AML | Sep 2031 |
| Fox Chase Cancer Center | Guadecitabine DNA methyltransferase inhibitor | DNMT1 | Phase 2 | Urothelial Carcinoma | – |
| Taiho Oncology | Decitabine (ASTX727) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| University of Southern California | Guadecitabine DNMT inhibitor | DNMT1, DNMT3A, DNMT3B | Phase 1 | Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Chronic Myelomonocytic Leukemia | Dec 2026 |
| Medical College of Wisconsin | Azacitadine DNA methyltransferase inhibitor | DNMT1 | Phase 1 | Acute Myeloid Leukemia, in Relapse | Jan 2027 |
| Otsuka | ASTX727 Decitabine and cedazuridine combination; decitabine is a DNA methyltransferase inhibitor | DNMT1 | Phase 1 | Myelodysplastic Syndromes | Jun 2027 |
| Memorial Sloan Kettering Cancer Center | Guadecitabine DNA methyltransferase (DNMT) inhibitor | DNMT1 | Phase 1 | Lung Cancer | Jul 2027 |
| The First Affiliated Hospital of Soochow University | Hypomethylating Agents DNA methyltransferase inhibitor (azacitidine or decitabine) | DNMT1 | Phase 1 | Acute Myeloid Leukemia (AML) | Sep 2027 |
| Taiho Pharmaceutical | ASTX030 (AZA + CED) DNA methyltransferase inhibitor (azacitidine) combined with cytidine deaminase inhibitor ( | DNMT1 | Phase 1 | Myelodysplastic Syndrome (MDS) | Dec 2027 |
| EpiDestiny | Decitabine DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 1 | Sickle Cell Disease; Multiple Sclerosis; Allogeneic Hematopoietic Stem Cell Transplantation (HSCT); AML (Acute Myeloid Leukemia) … | Oct 2028 |
| Otsuka | ASTX727 Oral decitabine and cedazuridine combination; cedazuridine inhibits cytidine deaminase to | DNMT1 | Phase 1 | Lower-risk Myelodysplastic; Malignant Peripheral Nerve Sheath Tumors (MPNST); Non Small Cell Lung Cancer; Neurological Cancer … | – |
| Ajjai Alva, MD | Guadecitabine DNA methyltransferase inhibitor | DNMT1 | Phase 1 | Advanced Kidney Cancer | – |
| Royal Marsden NHS Foundation Trust | Guadecitabine DNMT inhibitor; hypomethylating agent | DNMT1 | Phase 1 | Non Small Cell Lung Cancer | – |
Acute Myeloid Leukemia (71) Myelodysplastic Syndromes (14) AML (7) Chronic Myelomonocytic Leukemia (6) Acute Myeloid Leukemia (AML) (6) Leukemia, Myeloid, Acute (5) Solid Tumor (5) T-cell Acute Lymphoblastic Leukemia (4) Myeloid Malignancy (4) AML, Adult (4) Sickle Cell Disease (3) Hairy Cell Leukemia (3)
small molecule (11), mixed (6)
Taiho Oncology (2) Otsuka (2) University of Southern California (1) EpiDestiny (1) AbbVie (1) Ajjai Alva, MD (1) National Cancer Institute (NCI) (1) The First Affiliated Hospital of Soochow University (1) Royal Marsden NHS Foundation Trust (1) Bristol-Myers Squibb (1) Taiho Pharmaceutical (1) Medical College of Wisconsin (1) Fox Chase Cancer Center (1) Memorial Sloan Kettering Cancer Center (1) Virginia Commonwealth University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.